OncoSec Medical Inc (ONCSQ)

[hschlauch]

Yes, converting 30% of non-responders (to monotherapy Keytruda) would be outstanding. I have been estimating that T-vec in combination with Pembrolizumab may be similar to having somewhere between a 28%-38% BORR with non-responders. Therefore, converting 30% is potentially in line with the top metastatic melanoma stage III/IV data reported to date. If EP IL-12 was not demonstrating efficacy, we shouldn't see responses in the trial, obviously because they are dealing with a non-responder population.

Combination Yervoy (anti-CTLA4) and Opdivo (anti-PD1) demonstrate response rates on par with T-vec and Pembrolizumab, but the side effects are horrendous, most likely due to their systemic applications. Combination T-Vec and Pembrolizumab also don't appear to be eliminating visceral metastatic tumors in stage III/IV melanoma.

I would be very happy with a 30% BORR as well. We'll see what happens though.